The Use of Heliox in Obstructive Sleep Apnea Syndrome (HOSA)

Northwell Health

Status and phase

Completed

Phase 2

Conditions

Obstructive Sleep Apnea Syndrome

Treatments

Drug: Heliox

Study type

Interventional

Funder types

Other

Identifiers

NCT02135900

09-046

Details and patient eligibility

About

The goals of the project is to evaluate the effects of Heliox therapy on obstructive sleep apnea syndrome (OSAS).

Full description

Obstructive sleep apnea syndrome (OSAS) is a common condition affecting up to 2-4 % of the general population. The pathophysiologic consequences of OSA include: excessive daytime sleepiness leading to increased car and work related accidents; and increased incidence of hypertension (HTN), stroke and possibly coronary artery events. In addition, patients with severe and untreated obstructive sleep apnea (OSA) have increased mortality compared to patients with treated severe OSA.The main stay of treatment of OSAS is the application of continuous positive airway pressure (CPAP) during sleep. The main problem with CPAP therapy is compliance. Heliox, a mixture of oxygen and helium has been used for many years in the treatment of upper airway obstruction. In this study, the investigators will evaluate the effectiveness of Heliox in the treatment of OSAS. Adult subjects with the diagnosis of obstructive sleep apnea syndrome who are referred for repeat sleep study for CPAP titration will be evaluated.

Enrollment

32 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults 18 or older with obstructive sleep apnea syndrome (OSAS) presenting for CPAP titration.

Exclusion criteria

Professional singers.
Television or Radio hosts.
Disk Jockeys.
Subjects requiring oxygen therapy.
Subjects younger than 18 year old.
Pregnant women.
Patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume 1 (FEV1) less than 50%.
History of anatomic upper airway obstruction.
Uncontrolled asthma.